HomeMACK • NASDAQ
Merrimack Pharmaceuticals Inc
$14.72
Pre-market:
$14.72
(0.00%)0.00
Closed: Mar 19, 12:30:35 AM GMT-4 · USD · NASDAQ · Disclaimer
StockUS listed security
Previous close
$14.74
Day range
$14.68 - $14.75
Year range
$11.45 - $15.89
Market cap
213.68M USD
Avg Volume
162.48K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
Financials
Income Statement
Revenue
Net income
(USD)Dec 2023Y/Y change
Revenue
Operating expense
490.00K-19.28%
Net income
-240.00K51.22%
Net profit margin
Earnings per share
EBITDA
Effective tax rate
-5.26%
Total assets
Total liabilities
(USD)Dec 2023Y/Y change
Cash and short-term investments
18.88M-2.90%
Total assets
19.19M-3.27%
Total liabilities
441.00K-25.13%
Total equity
18.75M
Shares outstanding
14.52M
Price to book
11.25
Return on assets
-6.37%
Return on capital
-6.52%
Net change in cash
(USD)Dec 2023Y/Y change
Net income
-240.00K51.22%
Cash from operations
-295.00K-59.46%
Cash from investing
68.00K
Cash from financing
133.00K-97.96%
Net change in cash
-94.00K-101.48%
Free cash flow
-229.25K-212.44%
About
Merrimack Pharmaceuticals is a pharmaceutical company based in Cambridge, Massachusetts, United States. They specialize in developing drugs for the treatment of cancer. Merrimack's first FDA-approved drug was approved in 2015; Onivyde, a liposome encapsulated version of irinotecan is used for treating pancreatic adenocarcinoma. It was approved for use in the European Union the following year. Wikipedia
Founded
2000
Employees
27
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Google apps
Main menu